We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gene Expression Patterns Identified Associated with Multiple Sclerosis

By Biotechdaily staff writers
Posted on 07 Nov 2007
Gene expression patterns have been identified in white blood cells (WBCs) that are statistically associated with multiple sclerosis (MS), a disease of the central nervous system (CNS). More...
Genomic analysis also identified gene patterns associated with two recently approved therapies for MS.

MS is a chronic inflammatory disease that selectively destroys the myelin sheaths of neurons within the CNS, leading to loss of neurological function with unpredictable course and severity. The disease affects approximately 350,000 persons in the United States alone, and more than 25,000 new diagnoses are confirmed each year. Susceptibility to MS is determined by genetic and environmental factors that are not well understood, requiring a battery of expensive and in many cases invasive tests to arrive at a diagnosis.

Gene Logic (Gaithersburg, MD, USA) scientists evaluated the WBC samples using gene expression microarrays that enable comprehensive analysis of the human genome. They compared untreated MS samples with non-MS samples (both non-diseased and from other autoimmune diseases), as well as MS samples before and after treatment with Avonex (beta-interferon) and Copaxone (glatiramer acetate). Statistically significant gene expression differences between the groups were determined to identify gene sets.

"These studies lay the foundation for several MS diagnostics that could have significant clinical applications,” said Larry Tiffany, senior vice president and general manager of Genomics at Gene Logic. "A blood-based test that can definitively diagnose MS would clearly be of high value to physicians. A ‘rule-out' test demonstrating that a patient does not have MS would also be clinically useful, since it eliminates a lengthy, costly and often invasive medical work-up in many patients with symptoms similar to MS. Other potential applications of our comprehensive approach could be tests to monitor disease activity, identify sub-types of MS, and functionally assess drug activity.”

Gene Logic is using blood samples from the repository of the Accelerated Cure Project for Multiple Sclerosis (ACP), a non-profit organization that has assembled the largest multi-disciplinary bio-bank for MS research.


Related Links:
Gene Logic
Cure Project for Multiple Sclerosis

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Aspiration System
VACUSAFE
New
Thyroid Test
Anti-Thyroid EIA Test
New
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.